Exeter Respiratory Research & Innovation (ERI)
Exeter Respiratory Research & Innovation (ERI)
Read about our recent research endeavours below.
We are testing an investigational medicine called orvepitant as a treatment for chronic cough associated with idiopathic pulmonary fibrosis (IPF), a condition that causes scarring of the lungs. An investigational...
Continue reading...Primary Objective: To determine what is the clinical and cost effectiveness of ambulatory oxygen therapy (AOT) in patients with idiopathic pulmonary fibrosis (IPF) Inclusion Criteria: Clinically diagnosed IPF, confirmed by...
Continue reading...Orphan drugs are medicines for diagnosis, prevention or treatment of life-threatening or progressive disorders that are rare (affecting less than 1 in 2,000 people). An example is Idiopathic Pulmonary Fibrosis...
Continue reading...The purpose of this study is to evaluate the efficacy, safety, and tolerability of brensocatib as treatment for NCFBE. This is an experimental clinical research study of a study drug...
Continue reading...Fibrotic lung conditions result in scarring of the lung tissue. This causes shortness of breath and cough, and has an enormous impact on people’s quality of life. We currently know...
Continue reading...Some patients with Chronic Obstructive Pulmonary Disease (COPD) find it hard to clear sputum (phlegm) from the airways. Unfortunately, there’s no good evidence that shows the best treatment for patients....
Continue reading...Idiopathic Pulmonary Fibrosis is a disease which results in damage to the lung tissue. It is characterised by progressive loss of lung function (measured by breathing tests) and increasing breathlessness....
Continue reading...